MiMedx Group, Inc. (MDXG) introduced CHORIOFIX, a lyophilized human placental allograft that incorporates two chorion layers with an intact intermediate layer, on March 23, 2026. The dual‑sided chorion configuration eliminates the need for orientation during application and improves handling during positioning and suturing, making CHORIOFIX the company’s thickest product to date.
CHORIOFIX is designed for complex lower‑extremity wounds, including large deficits and deep tunneling wounds, which are among the most difficult wound types to treat. Early access evaluations by clinicians highlighted the product’s handling characteristics and anecdotal evidence of effective wound closure in challenging cases. One clinician noted, "I have used several MIMEDX products for complex lower extremity wound care in the hospital setting. In an early access evaluation of CHORIOFIX, I was impressed with the product's handling characteristics and the effective wound closure observed anecdotally in my patients. The naturally thicker composition is well‑suited for use in large deficits and deep, tunneling wounds, which represent some of the most difficult wound types to treat effectively."
The launch is part of MiMedx’s broader strategy to generate robust clinical evidence. CHORIOFIX has been added to the CAMPAIGN randomized controlled trial, which compares EPIEFFECT and CHORIOFIX against standard of care for non‑healing diabetic foot ulcers. The trial will provide data to support adoption and reimbursement for the new product.
Financially, MiMedx’s Q4 2025 results showed record revenue of $118.1 million, a 27% year‑over‑year increase, and net income of $15.19 million. Full‑year 2025 sales totaled $418.63 million, up from $348.88 million a year earlier. The company’s guidance for 2026 net sales is $340–$360 million, and gross margin for Q4 2025 was 84% (86% adjusted), up from 82% YoY. Management expects 2026 gross margin to be in the mid‑to‑upper 70s, reflecting lower wound average selling prices and the integration of new products.
CEO Joseph H. Capper said, "The short‑term disruptions caused by Medicare reimbursement changes in the Wound market will likely have an impact on our 2026 revenue. Once demand patterns normalize, we expect to gain significant volume over time. Meanwhile, we believe the clear momentum we have across the rest of our business — Surgical, international and Wound commercial pay — will provide continued profitability and cash flow." VP of Research & Development Michelle Massee added, "CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer."
The launch strengthens MiMedx’s competitive advantage through its proprietary PURION® process, which preserves biologic activity while providing a robust, clinically useful allograft. The thicker composition and dual‑sided design position CHORIOFIX to capture a share of the complex wound market, and the CAMPAIGN trial will supply evidence to support pricing and reimbursement strategies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.